目的:探讨司来吉兰联合普拉克索治疗帕金森病(PD)合并睡眠障碍的疗效。方法:抽取聊城市第三人民医院2018年12月至2019年7月收治的PD合并睡眠障碍患者96例，按随机数字表法分为研究组和对照组，每组48例。研究组予以司来吉兰合并普拉克索治疗，对照组予以单纯司来吉兰治疗，记录两组治疗前后精神行为症状、认知障碍、日常生活能力、睡眠质量的改善效果，统计两组治疗期间不良反应发生情况。结果:治疗前，两组神经精神科问卷(NPI)、蒙特利尔认知评估量表(MoCA)评分比较差异未见统计学意义(n P>0.05)；治疗后，两组NPI评分较治疗前下降，MoCA量表评分较治疗前提高(n P0.05). After treatment, the NPI score of the two groups decreased, and the MoCA score increased, compared with these indexes before treatment (n P<0.05); and the NPI and MoCA scores of the study group were better than those of the control group (n P0.05). After treatment, the ADL score of the study group was higher than that of the control group, and the PSQI score was lower than that of the control group (n P0.05).n Conclusions:The combination of selegiline and pramipexole in the treatment of PD patients with sleep disorders is conducive to improving their mental and behavioral symptoms, cognitive impairment, and ADL.